Novo Nordisk's new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer ...

Novo Nordisk Places Bet on CEO Shake-Up to Regain ... The latest licensing agreements for early-stage candidates like Amycretin and others bought from Septerna and United Laboratories ...

Amycretin: This is another agonist ... So, considering this context, do you think Novo Nordisk's 8% drop on the day of Lilly's announcement was justified? In my view, clearly not.

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

Seigerman acknowledged that Novo Nordisk's experimental small-molecule pill, amycretin, could be competitive long-term. But he said that won't happen soon, as the drug is not expected to launch ...

Seigerman acknowledged that Novo Nordisk's experimental small-molecule pill, amycretin, could be competitive long term. But he said that won't happen soon, as the drug is not expected to launch ...